Skip to main content
. Author manuscript; available in PMC: 2012 Jul 5.
Published in final edited form as: Oncogene. 2010 Mar 22;29(22):3185–3195. doi: 10.1038/onc.2010.75

Fig. 6. Engineered hNSC do not differentiate in mouse glioma model.

Fig. 6

hNSC-aaTSP-1 or control hNSC-GFP-Rluc were implanted in the close vicinity of established Gli36-EGFRvIII-FD gliomas. Representative images of brain sections of hNSC-aaTSP-1 mice sacrificed on day 12 and immunostained with nestin, Ki67, GFAP and MAP-2 antibodies. Different panels showing the expression of tumor cells (red), hNSC (green) and nestin, Ki67, GFAP or MAP-2 immunostaining (purple). NB-normal brain; T-tumor.